NR
NRXP.US NRX Pharmaceuticals Inc
- Market cap
- USD 95.6M
- P/E
- -
- P/B
- 2.90x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NRXP.US undervalued?
Graham numberThe Graham number of NRX Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NRX Pharmaceuticals Inc fundamental analysis
No fundamental analysis for NRX Pharmaceuticals Inc yet.
NRX Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation an…
Full company profileNRX Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NRX Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.23M | 4.34M |
| Gross Profit | - | -1.01M | - | -2.00K | -2.00K | -4.00K | -5.00K | -5.00K | 720K | 1.06M |
| Operating Income | -134K | -1.01M | -713K | -22.1M | -95.2M | -44.3M | -27.6M | -19.7M | -16.2M | -22.5M |
| EBITDA | -105K | 82.4K | 493K | -51.7M | -93.0M | -39.8M | -30.0M | -24.0M | -27.8M | -34.3M |
| Net Income | -105K | 66.1K | 408K | -51.8M | -93.1M | -39.8M | -30.2M | -25.1M | -28.6M | -35.9M |
| EPS | -0.12 | 0.07 | 0.80 | -95 | -1.98 | -0.60 | -3.98 | -2.39 | -1.34 | -0.95 |
| Balance Sheet | ||||||||||
| Total Assets | 69.6M | 70.8M | 32.1M | 2.94M | 32.7M | 25.8M | 7.32M | 3.65M | 13.0M | 34.2M |
| Total Liabilities | 93.2K | 1.26M | 2.57M | 46.7M | 11.9M | 18.4M | 19.0M | 26.9M | 28.9M | 34.3M |
| Shareholders' Equity | 69.5M | 69.5M | 29.5M | -43.8M | 20.8M | 7.41M | -11.7M | -23.2M | -15.9M | -170K |
| Cash & Short-term Investments | 449K | 11.1K | 6.00 | 1.86M | 27.6M | 20.1M | 4.60M | 1.44M | 7.80M | 26.7M |
| Total Debt | - | 690K | 1.95M | 797K | 518K | 10.5M | 9.16M | 6.58M | 631K | 1.25M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -136K | -473K | -793K | -2.27M | -37.7M | -39.8M | -21.7M | -10.6M | -14.1M | -26.3M |
| Capital Expenditure | 0.00 | 0.00 | 1.00 | 2.00K | 7.00K | 10.0K | 3.00K | 0.00 | 0.00 | 1.79M |
| Free Cash Flow | -136K | -473K | -793K | -2.27M | -37.7M | -39.8M | -21.7M | -10.6M | -14.1M | -28.1M |
| Ratios | ||||||||||
| ROE | -0.2% | 0.1% | 1.4% | - | -447.3% | -536.6% | - | - | - | - |
| ROA | -0.2% | 0.1% | 1.3% | -1,760.5% | -284.3% | -154.0% | -412.2% | -688.2% | -220.9% | -105.1% |
| Net Profit Margin | - | - | - | - | - | - | - | - | -2,336.5% | -827.6% |
| Debt to Equity | - | 0.01x | 0.07x | - | 0.02x | 1.42x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NRX Pharmaceuticals Inc dividends
NRX Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Apr 2, 2024.
Who owns NRX Pharmaceuticals Inc
- Insiders 4.95%
- Institutions 29.20%
- Public & others 65.85%
- Shares outstanding 43.6M
- Free float 37.4M
Top funds holding NRXP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.27M | 2.90% | 0.00% | Sep 2026 |
| AdvisorShares Psychedelics ETF | 601K | 1.38% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 206K | 0.47% | +42.97% | Sep 2026 |
| iShares Micro-Cap ETF | 102K | 0.23% | 0.00% | Oct 2026 |
| Abante Quant Value FI | 101K | 0.23% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 69.3K | 0.16% | +37.44% | Sep 2026 |
| Fidelity Series Total Market Index | 44.8K | 0.10% | 0.00% | Sep 2026 |
| Mandarine Global Microcap G EUR | 40.0K | 0.09% | -20.00% | Jul 2026 |
| Fidelity Nasdaq Composite Index | 22.0K | 0.05% | 0.00% | Aug 2026 |
| Vanguard Balanced Index Inv | 21.7K | 0.05% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 17.2K | 0.04% | +197.66% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 15.5K | 0.04% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 7.04K | 0.02% | +12.81% | Sep 2026 |
| Victory Extended Market Index | 4.37K | 0.01% | +2.25% | Sep 2026 |
| JHVIT Total Stock Market Index I | 747.00 | 0.00% | 0.00% | Sep 2026 |
| Avantis America Equity ETF USD Acc | 23.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding NRXP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| B Group, Inc | 4.09M | 9.37% | +36.39% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.62M | 3.71% | +39.47% | Jun 2026 |
| Ameriprise Financial Inc | 929K | 2.13% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 894K | 2.05% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 680K | 1.56% | 0.00% | Jun 2026 |
| AdvisorShares Investments, LLC | 659K | 1.51% | +56.73% | Jun 2026 |
| Commonwealth Equity Services, LLC | 454K | 1.04% | +14.34% | Jun 2026 |
| UBS Group AG | 423K | 0.97% | +1,577.23% | Jun 2026 |
| Geode Capital Management, LLC | 315K | 0.72% | +1.47% | Jun 2026 |
| BlackRock Inc | 220K | 0.51% | +122.70% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 195K | 0.45% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 183K | 0.42% | +7.75% | Jun 2026 |
| Jane Street Group LLC | 119K | 0.27% | +169.56% | Jun 2026 |
| Bleakley Financial Group LLC | 117K | 0.27% | +0.01% | Jun 2026 |
| State Street Corp | 116K | 0.27% | +33.45% | Jun 2026 |
| HRT FINANCIAL LLC | 101K | 0.23% | 0.00% | Jun 2026 |
| Northern Trust Corp | 63.0K | 0.14% | +44.82% | Jun 2026 |
| Chicago Partners Investment Group LLC | 46.4K | 0.11% | +34.54% | Jun 2026 |
| Quadrature Capital Limited | 43.6K | 0.10% | 0.00% | Jun 2026 |
| One Wealth Management Investment & Advisory Services LLC | 43.3K | 0.10% | 0.00% | Jun 2026 |
NRX Pharmaceuticals Inc company profile
- Company name
- NRX Pharmaceuticals Inc
- Ticker
- NRXP.US
- Exchange
- USA Stocks
- Listed since
- Dec 4, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Fiscal year end
- December
- Address
- 1201 N. Market Street, Wilmington, DE, United States, 19801
- Phone
- 484 254 6134
- Website
- nrxpharma.com
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
NRX Pharmaceuticals Inc management
4- Dr. Jonathan C. Javitt M.D., M.P.H.Co-Founder, Chairman & CEO · born 1957
- Mr. Michael S. Abrams M.B.A.CFO & Treasurer · born 1970
- Prof. Joshua C. Brown M.D., Ph.D.Chief Medical Innovation Officer
- Mr. Glenn D. TysonChief Commercial Officer